<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333732</url>
  </required_header>
  <id_info>
    <org_study_id>202004099</org_study_id>
    <secondary_id>INV-017499</secondary_id>
    <nct_id>NCT04333732</nct_id>
  </id_info>
  <brief_title>CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION</brief_title>
  <acronym>CROWN CORONA</acronym>
  <official_title>An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>COVID -19 Therapeutics Accelerator</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using
      combinations of approved and safe repurposed interventions, with complementary mechanisms of
      action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CROWN CORONATION is an international, Bayesian platform adaptive, randomized,
      placebo-controlled trial assessing the effectiveness of candidate interventions in preventing
      COVID-19 disease in healthcare workers.

      Randomization will be stratified by age (&lt;50 and ≥50) and site. Participants will be
      healthcare workers at risk of contracting SARS-CoV-2. Participants will be randomized into
      one of two arms:

        -  Education and surveillance plus MR or MMR vaccine

        -  Education and surveillance plus Placebo

      While the initial intervention to be tested on the platform will be the MR or MMR vaccine,
      other interventions might be added or removed over the course of the trial. The trial will
      evaluate which of the intervention arms is most effective at decreasing the incidence of
      symptomatic COVID-19 disease, without unacceptable side effects or safety events.

      All participants will require be required to have a mobile phone to participate. This is
      standard in all the countries in this study. Most, but not all, will also have a smartphone.
      Participants will complete weekly data logs via SMS texting. Follow-up information will be
      collected until approximately 5 months after the end of treatment or death. Participants who
      develop symptomatic COVID-19 during the last month of observation will at a minimum be
      followed-up until symptom resolution and at a maximum until 6 months after randomization
      (whichever comes first). Telemedicine approaches to collecting information on participants
      will be used where possible. The trial will provide adherence support interventions that have
      been shown in randomized controlled trials to improve adherence to Human Immunodeficiency
      Virus treatment and adapted for HIV Pre-Exposure Prophylaxis (HIV PrEP) (e.g. two-way SMS
      with check in for those that report symptoms or adverse events). The database will be hosted
      on UK-based servers which are expected to be managed by Sealed Envelope Ltd. Local
      investigators will have access to the part of the CRF to enable recording of outcome data
      and/or severity of COVID-19 symptoms. Participants will be given a secure login to enable
      them to complete an initial participant health questionnaire and the regular data logs. It is
      envisaged that these will be completed at least weekly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An international, multi-site, randomized, placebo-controlled, Bayesian platform clinical trial. Initially there will be 2 arms, but we anticipate adding intervention arms to the platform. Combining interventions, allowing assessment of potential interactions, will be considered when arms are added.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>For the MR or MMR vaccine, there will be a placebo vaccine. Attempts will be made to maintain masking for other interventions (e.g. oral tablets) added to the platform by including suitable placebo options.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic COVID-19</measure>
    <time_frame>60 days</time_frame>
    <description>To determine the incidence of the trial intervention(s) in preventing laboratory test-confirmed, symptomatic COVID19 (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea), in healthcare workers with repeated exposures to SARS-CoV-2 by day 60 after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of COVID-19 over the study period</measure>
    <time_frame>60 days</time_frame>
    <description>Severity of COVID-19 will be graded on a simplified version of the ordinal World Health Organization COVID-19 severity scale (WHO COVID-19 severity scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of preventing/reducing SARS-CoV-2 infection</measure>
    <time_frame>5 months</time_frame>
    <description>SARS-CoV-2 infection (by serology) over up to 5 months of follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>M-M-R II ®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Education and surveillance plus M-M-R II ®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Education and surveillance plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR or M-M-R II ® vaccine</intervention_name>
    <description>Education and surveillance plus MR or M-M-R II ® vaccine</description>
    <arm_group_label>M-M-R II ®</arm_group_label>
    <other_name>Merck</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Volunteers without clinical evidence of COVID-19 infection aged 18 years and older.

          2. Healthcare workers based in a primary, secondary or tertiary healthcare setting with a
             high risk of developing COVID-19 due to their potential exposure to patients with
             SARS-CoV-2 infection.

          3. Must have a mobile phone and access to the Internet for data collection purposes.

          4. Participants who are willing and able to provide informed consent via an electronic
             consent process.

        Exclusion criteria

          1. Prior enrollment into other COVID-19 interventional prevention or treatment trials
             (observational trials not excluded).

          2. Self-reported or diagnosed current infection with SARS-CoV-2 or previous COVID-19
             diagnosis.

          3. Self-reported current acute respiratory infection.

          4. Concurrent and/or recent involvement in other research or use of the investigational
             product, a product considered to be equivalent to the investigational product, or any
             other product that is likely to interfere with the investigational products in this
             trial used within three months of study enrolment.

          5. Self-reported known allergies to any of the IMPs and excipients of the IMPs and
             placebo.

          6. Self-reported presence or history of the conditions listed in the appendices.

          7. Self-reported current use of medication known to interact with any of the medications
             listed in the appendices.

          8. Inability or unwillingness to be followed up for the trial period.

        For M-M-R II

          -  Pregnant women.

          -  Individuals receiving high dose corticosteroids, other immuno-suppressive drugs,
             alkylating agents or anti-metabolites.

          -  Individuals undergoing radiotherapy.

          -  Any malignant disease either untreated or currently undergoing therapy.

          -  History of administration of gammaglobulin or blood transfusions within the previous 3
             months.

          -  Participants with an allergy to the MR (MMR) vaccine or its components, including
             neomycin.

          -  Idiopathic thrombocytopenic purpura (ITP)

          -  Untreated tuberculosis

          -  Prior receipt of any vaccines (licensed or investigational) ≤30 days before enrollment

          -  Planned receipt of any vaccine other than the study intervention within 30 days before
             and after the study vaccination

          -  Prior receipt of an investigational or licensed vaccine likely to impact on
             interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus
             vaccines).

          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including
             untreated HIV infection with a CD4T count &lt;200 /mL

          -  Asplenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S. Avidan, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univeristy School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramani Moonesinghe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Rees, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wits University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Yun, BS, CCRP</last_name>
    <phone>314-273-2240</phone>
    <email>crowntrial@email.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry McKinnon, MS, CCRP</last_name>
    <phone>314-286-1768</phone>
    <email>crowntrial@email.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Yun, BS, CCRP</last_name>
      <phone>314-273-2240</phone>
      <email>CrownTrial@email.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sherry McKinnon, MS, CCRP</last_name>
      <phone>314-286-1768</phone>
      <email>CrownTrial@email.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael S. Avidan, MBBCh, FCASA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Politi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Dubberke, MD, MSPH, FSHEA, FIDSA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elvin Geng, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Graham Colditz, MD, DrPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Lenz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Davila-Roman, MD, FACC, FASE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Powderly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shabaana A. Khader, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Health Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Mazer, MD</last_name>
      <phone>(416) 864-5825</phone>
      <email>David.Mazer@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>David Mazer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ghana Medical Centre</name>
      <address>
        <city>Accra</city>
        <state>Greater Accra Region</state>
        <zip>00233</zip>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Kyei, MD, PhD</last_name>
      <phone>+233551989937</phone>
      <email>mailto:gkyei@noguchi.ug.edu.gh</email>
    </contact>
    <contact_backup>
      <last_name>Nana Adwoa Dsane, MA</last_name>
      <phone>+233243376304</phone>
    </contact_backup>
    <investigator>
      <last_name>Kwadwo Koram, MB ChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <zip>Dublin 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellen O'Sullivan, MD, FRCA,FCAI</last_name>
      <phone>353876993178</phone>
      <email>ellenosullivan2000@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mihai G Netea, MD PhD</last_name>
      <phone>+31-24-3618819</phone>
      <email>Mihai.Netea@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitas Academic Hospital</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edwin Turton, MBChB, Dip PEC, DA, MMed, FCA</last_name>
      <phone>+27 82 804 6839</phone>
      <email>turtonew@ufs.ac.za</email>
    </contact>
    <investigator>
      <last_name>Edwin Turton, MBChB, Dip PEC, DA, MMed, FCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wits RHI, University of the Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sinead Delany-Moretlwe, MBChB, PhD, DTM&amp;H</last_name>
      <phone>+27 82 377 6275</phone>
      <email>sdelany@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Moorhouse, MBChB</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gloria Maimela, MBBCh MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saiqa Mullick, MBBCh PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Martin, MBBCh MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steve Biko Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Mathijs, MBChB, MPharmMed</last_name>
      <phone>+27 836506425</phone>
      <email>sandra.spijkerman@up.ac.za</email>
    </contact>
    <investigator>
      <last_name>Sophie Mathijs, MBChB, MPharmMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Coenraad Koegelenberg, MBChB, MMED, FCP, MRCP, PhD</last_name>
      <phone>+27 833201307</phone>
      <email>coeniefn@sun.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Sean Chetty, MBChB, FCA, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Coenraad Koegelenberg, MBChB, MMED, FCP, MRCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Chetty, MBChB, FCA, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Biccard, MBChB,FCA,PhD</last_name>
      <phone>+27 21 4045015</phone>
      <email>bruce.biccard@uct.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Leon du Toit, MBChB, FCA(SA)</last_name>
      <phone>+27 (84) 5757330</phone>
      <email>leon.alive@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Biccard, MBChB,FCA,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leon du Toit, MBChB, FCA(SA)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willem Stassen, BTech, MPhil, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Alan Wallis, MBChB, FCS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Joubert, MBChB, FCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda-Gail Bekker, MBChB, DTM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Orrell, MBChB MMed MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lulu Nair, MBChB, DCH, DTM&amp;H, MPH,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Gill, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Ward, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Graeme Meintjes, MBChB, FRCP, FCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Hatherill, MBChB, DCH, MRCP, FCPaed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorraine Swanepoel, B.Sc.Pharm, Hons. B.Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute Kampala, Uganda</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Castelnuovo, PhD</last_name>
      <phone>+256786623613</phone>
      <email>bcastelnuovo@idi.co.ug</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Okoboi, Master</last_name>
      <phone>+256704817590</phone>
      <email>sokoboi@idi.co.ug</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Castelnuovo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Okoboi, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Laker, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Lovat, MD, PhD</last_name>
      <phone>020 3447 7488</phone>
      <email>laurence.lovat@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Laurence Lovat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim-Moulay Dehbi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nick Freemantle, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dermot McGuckin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Jones, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramani Moonesinghe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josheph Standing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Hill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levy Mwanawasa University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <zip>10101</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laston Chikoya, BSc, MBChB, MMed, MD</last_name>
      <phone>+260977349415</phone>
      <email>chikoyal@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bright Nsokolo, BScHB, MB ChB, MMED</last_name>
      <phone>+260977884895</phone>
      <email>b_nsokolo@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Izukanji Sikazwe, MBChB, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roma Chilengi, MBChB, MSc, ACCRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bolton, MBBCh, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikumbutso Chipeta, BScHB, MB ChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bright Nsokolo, BScHB, MB ChB, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lloyd Mulenga, BScHB, MBCHB, MScID, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia [CIDRZ]</name>
      <address>
        <city>Lusaka</city>
        <zip>H8R9+9V</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Izukanji Sikazwe</last_name>
    </contact>
    <investigator>
      <last_name>Izukanji Sikazwe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roma Chilengi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bolton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikumbutso Chipeta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Trials Research Centre</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nyaradzo Mavis Mgodi, MBChB, MMed</last_name>
      <phone>+263 772 264 616</phone>
      <email>nmgodi@uzchs-ctrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Teaclar Gamuchirai Nematadzira, : MBChB, Msc</last_name>
      <email>tnematadzira@uzchs-ctrc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nyaradzo Mavis Mgodi, MBChB, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teaclar Gamuchirai Nematadzira, MBChB, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gift Tafadzwa Chareka, Bachelor of Pharm, MscClin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Taguma Matubu, Bachelor Lab Sciences</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ghana</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Michael Avidan</investigator_full_name>
    <investigator_title>Professor of Anesthesiology and Surgery</investigator_title>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>Health care workers</keyword>
  <keyword>M-M-R II ®</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From 3 months after the last patient last visit onward.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

